The Readiness Illusion: Escaping Commercial Gravity

There is a moment every CGT company knows. The science is solid. The differentiation is real. The team believes deeply in what they’re building. And yet the commercial story stays inside, held carefully, waiting for one more condition to be met before sharing it with the market.

One more data point. One more partnership confirmation. One more regulatory signal.

In a field this rigorous, that instinct makes complete sense. Scientific caution is part of the culture and rightly so. But something significant has changed in CGT. And the companies recognizing it earliest are the ones with the clearest commercial ascent right now.

The Field Has Matured. And So Have the Rules.
CGT is no longer held together primarily by relationships and promise. Clinical outcomes are accumulating. Manufacturing track records exist. Regulatory precedents are being established.

Investors and partners now evaluate scientific position and commercial position together. The companies that have built both in parallel are gaining ground in ways that are increasingly difficult to close.

This is genuinely exciting news for the ecosystem. It means the science is proving itself. It means the market is sophisticated enough to reward real differentiation. It means the companies doing the work, scientifically and commercially, are being recognized for it.

The opportunity for every company in this space is to make sure their commercial position reflects the quality of what they have actually built.

What Commercial Authority Looks Like Now
In early CGT, trust in the team was often the primary currency. Relationships carried companies through enormous uncertainty because the science was so new that personal credibility filled the gaps data could not.

That dynamic has not disappeared. Relationships still matter enormously in this ecosystem. But the market now expects both. A credible scientific position and a clear commercial one.

The companies gaining preferred partner status today entered commercial conversations early. Not because their data was complete. Because they had a clear point of view about who they serve and why it matters.

Commercial authority in a maturing market comes from one thing: A defined position, consistently communicated to a specific audience, over enough time to build recognition and trust before a transaction is ever on the table.

That sequence cannot be rushed. But it can be started.

The Inversion Worth Considering
The companies with the clearest commercial ascent right now are not necessarily moving faster or taking on more risk. They are simply inverting the sequence.

Position first. Validate in market. Refine based on signal.

Rather than waiting for internal certainty before beginning external presence.

The first approach means that by the time a commercial conversation becomes relevant, the relationship foundation already exists. The second means arriving into a market that has already formed its reference points and preferred partners and working backward from there.

Starting that foundation earlier is simply the smarter commercial investment.

The Question Worth Sitting With
CMC readiness and commercial readiness are not the same timeline. The most commercially successful companies in this space have learned to run them in parallel rather than in sequence.

What specific claim about your platform, process, or capability could you make publicly right now, with complete scientific integrity, that would be immediately meaningful to your target partner, customer, or investor?

For most companies the answer exists. The science supports it. The differentiation is real.

What is often missing is the commercial translation layer — the ability to take what is known internally and make it legible and compelling to the market that needs to hear it.

That translation is where commercial ascent begins. The best time to start is always earlier than feels necessary. It is never as late as it appears.

The window in CGT is real. And it is wide open for the companies ready to rise into it.

Susan Nichols is CEO and Managing Director of Propel Biosciences, a commercialization consultancy serving CDMOs, tools platforms, and diagnostics companies in the cell and gene therapy ecosystem.